Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Lennar Corporation (LEN) Price & Performance

Incyte CorporationTrade
Lennar CorporationTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Lennar Corporation — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Lennar Corporation trades at $87.46 (market cap $21.05B). The key difference: Incyte Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYLEN
Market Cap
$24.54B$21.05B
Sector
HealthConsumer Cyclical
52-Week High
$129.93$142.40
52-Week Low
$81.61$81.84
Enterprise Value
$20.04B$24.93B
Dividend Yield
2.28%

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Lennar Corporation

Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.

Read more on LEN